TENX
Tenax Therapeutics Inc
1.90$
+2.1%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -21.9% | -68.0% | -57.6% | +34.8% | -52.3% | +7.9% | -12.8% | -43.2% | +243.2% | +727.5% | +7.8% | |
| – | -65.1% | -33.7% | -40.8% | +65.2% | -53.6% | +9.9% | -16.3% | -43.6% | +264.1% | +727.5% | +7.8% | |
| – | -93.7% | +173.1% | -83.9% | +670.6% | -60.3% | +27.4% | -10.7% | -62.0% | +361.1% | +868.6% | +2.9% | |
| – | -65.4% | -34.2% | -41.8% | +66.5% | -58.0% | +24.3% | -16.8% | -62.0% | +361.1% | +868.6% | +2.9% | |
| – | -25.2% | +46.8% | -30.9% | -100.0% | – | – | – | – | – | – | – | |
| – | -59.1% | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | -28.9% | -46.6% | -47.9% | -14.3% | -23.1% | +887.2% | +355.3% | – | – | – | – | |
| – | +0.0% | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | -4.3% | +0.0% | -100.0% | – | – | – | – | – | – | – | – | |
| – | +19.2% | -50.7% | -83.7% | +55.2% | +65.6% | -13.5% | -22.1% | +9.4% | +87.6% | +30.9% | +52.5% | |
| – | +79.0% | +34.7% | -83.7% | +55.2% | +61.7% | -16.3% | -26.2% | +18.1% | +94.1% | +30.9% | +52.5% | |
| – | -56.4% | – | – | – | – | +62.4% | -40.7% | +593.8% | -32.6% | – | – | |
| – | +136.5% | -25.2% | -15.9% | +22.5% | +121.5% | -54.4% | +13.4% | -47.8% | +362.3% | +52.3% | +91.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -27.1% | -71.6% | -48.2% | +32.5% | -68.0% | +22.6% | -8.2% | -64.8% | +442.5% | +1,036.0% | +5.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.1% | +0.1% | +0.3% | +3.8% | +323.2% | +19.7% | +177.5% | +43.0% | +1,250.9% | +6,046.9% | +156.8% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.